Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
FOR IMMEDIATE RELEASE Manufacturing has begun for Cancer Advances’ Lead Product Durham, NC, May 5, 2016— Cancer Advances Inc., a wholly owned subsidiary of Cato Holding Company, is excited to announce that drug manufacturing efforts for their lead product are underway. Manufacturing activities have been initiated for Cancer Advances’ lead product G17DT Immunogen. This work has been contracted with Nova Laboratories (Leicester, UK) and production of initial GMP batches are planned for this summer. It is anticipated that production of the drug substance and subsequent manufacture of drug product will be completed in a 3-6 month timeframe. Cancer Advances is excited that the manufacturing activities have been initiated and look forward to the availability of clinical trial materials for on-going studies in the near future. About Cancer Advances Inc. Cancer Advances Inc., a wholly owned subsidiary of Cato Holding Company, is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio. Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html Contact: Lynda Sutton President Cancer Advances, Inc. Phone: 919-361-2162 Email: [email protected]